William Guyer - 01 Dec 2025 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Role
Chief Development Officer
Signature
/s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer.
Issuer symbol
CORT
Transactions as of
01 Dec 2025
Net transactions value
-$1,150,655
Form type
4
Filing time
03 Dec 2025, 21:19:27 UTC
Previous filing
26 Nov 2025
Next filing
08 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Guyer William Chief Development Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 101 REDWOOD SHORES PARKWAY, REDWOOD CITY /s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer. 03 Dec 2025 0001879013

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CORT Common Stock Award $17,871 +224 $79.78 224 01 Dec 2025 Direct F1, F2
transaction CORT Common Stock Award $0 +224 +100% $0.000000 448 01 Dec 2025 Direct F3
transaction CORT Common Stock Gift $0 -787 -100% $0.000000 0 02 Dec 2025 The Lake Bainwood Living Trust F4
transaction CORT Common Stock Other $0 +787 +176% $0.000000 1,235 02 Dec 2025 Direct F5
transaction CORT Common Stock Options Exercise $433,000 +20,000 +1619% $21.65 21,235 02 Dec 2025 Direct
transaction CORT Common Stock Sale $1,549,766 -19,360 -91% $80.05 1,875 02 Dec 2025 Direct F6, F7
transaction CORT Common Stock Sale $51,760 -640 -34% $80.88 1,235 02 Dec 2025 Direct F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CORT Stock option (right to buy) Options Exercise $0 -20,000 -6.9% $0.000000 270,000 02 Dec 2025 Common Stock 20,000 $21.65 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on December 1, 2025.
F2 In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F3 Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
F4 Represents the shares held by The Lake Bainwood Living Trust of which the Reporting Person is a co-trustee.
F5 Transfer of shares without consideration to the Reporting Person.
F6 This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
F7 Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.78 to $80.68 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F8 Fully exercisable.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.